Generalized Myasthenia Clinical Trials

31 recruitingLast updated: July 25, 2026

There are 31 actively recruiting generalized myasthenia clinical trials across 34 countries. Studies span Phase 3, Phase 2, Phase 1, Phase 4, Early Phase 1, Not Applicable. Top locations include Warsaw, Poland, London, United Kingdom, Naples, Italy. Updated daily from ClinicalTrials.gov.


Generalized Myasthenia Trials at a Glance

31 actively recruiting trials for generalized myasthenia are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 3 with 14 trials, with the heaviest enrollment activity in Warsaw, London, and Naples. Lead sponsors running generalized myasthenia studies include argenx, Alexion Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Browse generalized myasthenia trials by phase

Treatments under study

About Generalized Myasthenia Clinical Trials

Looking for clinical trials for Generalized Myasthenia? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Generalized Myasthenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Generalized Myasthenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting
Phase 2

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Myasthenia Gravis (MG)gMGAChR-Ab Seropositive Generalized Myasthenia Gravis+1 more
argenx40 enrolled2 locationsNCT07673627
Recruiting
Phase 3

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled145 locationsNCT06463587
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled7 locationsNCT07247279
Recruiting
Phase 2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis
Amgen15 enrolled4 locationsNCT06987539
Recruiting
Phase 2Phase 3

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled22 locationsNCT06193889
Recruiting
Phase 2Phase 3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 1Phase 2

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled11 locationsNCT06704269
Recruiting
Phase 3

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled125 locationsNCT06517758
Recruiting
Phase 2Phase 3

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled14 locationsNCT06149559
Recruiting
Phase 3

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Generalized Myasthenia Gravis
Vor Biopharma180 enrolled111 locationsNCT06456580
Recruiting

Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

Generalized Myasthenia Gravis
Centre Hospitalier Universitaire de Nice50 enrolled1 locationNCT07570589
Recruiting
Phase 3

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled84 locationsNCT07039916
Recruiting
Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled15 locationsNCT07284420
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled18 locationsNCT07294170
Recruiting
Phase 2Phase 3

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
argenx12 enrolled20 locationsNCT06392386
Recruiting
Phase 3

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled129 locationsNCT06744920
Recruiting

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

Generalized Myasthenia Gravis (gMG)gMG
argenx100 enrolled30 locationsNCT07595653
Recruiting
Phase 2Phase 3

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Generalized Myasthenia Gravis
Shanghai Jiaolian Drug Research and Development Co., Ltd104 enrolled18 locationsNCT06447597
Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting
Phase 4

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.75 enrolled12 locationsNCT07221838